Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT01018849 · ClinicalTrials.gov registry record · NA

Role of Vitamin D in Secondary Prevention of Cardiovascular Events

A NA study of Cardiovascular Disease, sponsored by Creighton University.

Completed
Registry status
NA
Development phase
24
Enrollment target
2
Study locations

NCT01018849: Completed NA study of Cardiovascular Disease, sponsored by Creighton University.

NCT01018849 is a NA study of Cardiovascular Disease that has completed, run by Creighton University. The registered enrollment target is 24 participants, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (99% lower). The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT01018849, a NA study of Cardiovascular Disease, has completed, sponsored by Creighton University.

COMPLETED
Registry status
NA
Development phase
24 participants
Enrollment target
2
Study locations

Study Summary

The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienced at least one cardiovascular event. This study will investigate if the addition of 150,000 international units of cholecalciferol (vitamin D3) by mouth every 2 months to a subject's medication regimen will prevent further cardiovascular events.

Conditions Studied

Interventions

  • DIETARY_SUPPLEMENT Cholecalciferol
  • DIETARY_SUPPLEMENT Placebo

Study Locations (2)

Nebraska

  • The Cardiac Center at Creighton University - Omaha
  • University of Nebraska Medical Center - Omaha

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2009-07
Est. Completion 2015-05
Phase NA
Creighton University

98 total trials

What the finished NCT01018849 record still lists

NCT01018849 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 24 participants, a relatively small participant target, below the 2,697-participant average among 137 other Cardiovascular Disease trials with a reported enrollment target (99% lower).

The record links to 1 condition, with Cardiovascular Disease appearing as the primary indexed condition, and to 2 interventions - of which Cholecalciferol is the first listed.

NCT01018849 reports a single indexed study location in Nebraska.

Frequently Asked Questions

What is clinical trial NCT01018849 about?

NCT01018849 is a clinical study titled "Role of Vitamin D in Secondary Prevention of Cardiovascular Events". The purpose of this study is to determine if Vitamin D supplementation helps prevent recurrent cardiovascular events, such as heart attack or stroke, in patients who have already experienced at least one cardiovascular event. This study will investigate if the addition of 150,000 international units...

What is the current status of trial NCT01018849?

This trial is currently completed. It is a NA study. The enrollment target is 24 participants. The study started on 2009-07. Estimated completion is 2015-05.

What conditions does trial NCT01018849 study?

This clinical trial studies the following conditions: Cardiovascular Disease.

What interventions are being tested in trial NCT01018849?

The interventions under investigation include: Cholecalciferol (DIETARY_SUPPLEMENT), Placebo (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT01018849?

This trial is sponsored by Creighton University, which has 98 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT01018849 being conducted?

This trial has 2 study locations across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Cardiovascular Disease

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT01018849's enrollment target sits among peer trials

24 128th of 137 higher than 10 of 137 other Cardiovascular Disease trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Cardiovascular Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02331979 · 24 participants · NA

    Improving Bladder Function in SCI by Neuromodulation

  • NCT03096197 · 24 participants · NA

    Exoskeleton and Spinal Cord Stimulation for SCI

  • NCT03223922 · 24 participants · NA

    Neurocognitive Functioning With Genu-Sparing Whole Brain Radiation Therapy for Brain Metastases

  • NCT03326921 · 24 participants · Phase 1

    HA-1 T TCR T Cell Immunotherapy for the Treatment of Patients With Relapsed or Refractory Acute Leukemia After Donor Stem Cell Transplant

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT01018849, the US trial registry maintained by the National Library of Medicine. NCT01018849 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.